Boiardi A, Salmaggi A, Pozzi A, Broggi G, Silvani A
Department of Neurology, Istituto Nazionale Neurologico Carlo Besta, Milano, Italy.
J Neurooncol. 1996 Feb;27(2):157-62. doi: 10.1007/BF00177479.
We undertook a phase I-II trail of loco-regional mitoxantrone in 12 patients affected by malignant gliomas. Mitoxantrone was delivered at tumor recurrence by Ommaya reservoir, with 2 cycles and a 1 month interval between each cycle, in conjunction with systemic chemotherapy (8 pts) or not (4 pts). Treatment tolerability was good, and 9 of the patients showed either response or stable disease at the end of the treatment schedule. Regardless of associated chemotherapy, time to further tumor progression was at 6 months. A combination of early systemic and loco-regional chemotherapy with surgery and radiotherapy seems worth while pursuing in the therapeutic approach to malignant gliomas.
我们对12例恶性胶质瘤患者进行了米托蒽醌局部区域治疗的I-II期试验。米托蒽醌在肿瘤复发时通过奥马亚贮液器给药，共2个周期，每个周期间隔1个月，联合全身化疗（8例）或不联合（4例）。治疗耐受性良好，9例患者在治疗方案结束时显示有反应或病情稳定。无论是否联合化疗，至肿瘤进一步进展的时间为6个月。在恶性胶质瘤的治疗方法中，早期全身和局部区域化疗联合手术及放疗似乎值得探索。
